Stryker reported strong operating results for the second quarter of 2025 on July 31, 2025, delivering double-digit sales and adjusted earnings per share growth. Consolidated net sales increased 11.1% to $6.0 billion, with organic net sales growing 10.2%, driven by a 9.7% increase in unit volume. The MedSurg and Neurotechnology segment saw organic growth of 11.0%, while Orthopaedics grew 9.0% organically, excluding the divested Spinal implant business.
Adjusted net earnings per diluted share increased 11.4% to $3.13, surpassing analyst estimates. Reported net earnings increased 7.2% to $884 million, and reported diluted EPS rose 7.0% to $2.29. The adjusted operating income margin expanded to 25.7%, reflecting continued operational execution and leverage from sales growth.
Considering its year-to-date results and operational momentum, Stryker raised its full-year 2025 organic net sales growth guidance to a range of 9.5% to 10.0%. The company also raised its adjusted net earnings per diluted share guidance to between $13.40 and $13.60. Furthermore, Stryker lowered its estimated net impact from tariffs in 2025 to approximately $175 million, down from the previous estimate of $200 million, reflecting updates on bilateral U.S.-China tariffs and a proposed U.S.-EU tariff framework.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.